Treace Medical Concepts earnings missed, revenue topped estimates
#Treace Medical Concepts #TMCI stock #Earnings Report #Revenue Estimates #EPS Miss #Financial Health #NASDAQ
📌 Key Takeaways
- Treace Medical Concepts missed Q4 EPS estimates by $0.01
- Company topped Q4 revenue estimates with $61.82M
- Stock price has declined significantly (25.80% in 3 months, 76.51% in 12 months)
- Company has seen positive EPS revisions in recent months
- Financial Health score remains 'good performance'
📖 Full Retelling
Treace Medical Concepts (NASDAQ: TMCI) reported fourth quarter earnings on February 27, 2026, revealing that while their revenue topped analyst estimates, earnings per share missed expectations, causing concern among investors about the company's financial performance. The medical technology company posted a quarterly EPS of -$0.16, which fell short of the analyst consensus estimate of -$0.15 by $0.01. However, Treace managed to exceed revenue expectations, reporting $61.82 million compared to the $61.72 million predicted by analysts. Despite beating revenue estimates, the company's stock performance has been poor, closing at $2.10 and experiencing significant declines of 25.80% over the past three months and 76.51% over the past twelve months. Interestingly, despite the recent poor stock performance, Treace Medical Concepts has seen 3 positive EPS revisions and 0 negative EPS revisions in the last 90 days, suggesting some analyst optimism about the company's future prospects. According to InvestingPro, the company maintains a 'good performance' Financial Health score, indicating that despite current challenges, its fundamental financial position remains relatively strong.
🏷️ Themes
Earnings Report, Stock Performance, Financial Health
📚 Related People & Topics
Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical device company, headquartered in Ponte Vedra Beach, Florida, specializing in the design, manufacture, and marketing of foot and ankle surgical devices and biologics. Lapiplasty, Treace’s novel primary surgical product, advanced the treatment of bunions, sur...
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Netflix soars after declining to match Paramount Skydance bid for Warner Bros Gold prices steady; on track for strong Feb gains Dorsey’s Block slashes workforce 40% to embrace AI overhaul, shares gain Paramount wins Warner bidding war; Block surges - what’s moving markets (South Africa Philippines Nigeria) Treace Medical Concepts earnings missed, revenue topped estimates By Investing.com Earnings Published 02/27/2026, 07:28 AM Treace Medical Concepts earnings missed, revenue topped estimates 0 TMCI 2.94% Investing.com - Treace Medical Concepts (NASDAQ: TMCI ) reported fourth quarter EPS of $-0.16, worse than the analyst estimate of $-0.15. Revenue for the quarter came in at $61.82M versus the consensus estimate of $61.72M. Treace Medical Concepts’s stock price closed at $2.10. It is down -25.80% in the last 3 months and down -76.51% in the last 12 months. Treace Medical Concepts saw 3 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Treace Medical Concepts’s stock price’s past reactions to earnings here . According to InvestingPro , Treace Medical Concepts’s Financial Health score is " good performance ". Check out Treace Medical Concepts’s recent earnings performance , and Treace Medical Concepts’s financials here . Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
Read full article at source